Page last updated: 2024-10-28

hydroxychloroquine and Endocarditis

hydroxychloroquine has been researched along with Endocarditis in 6 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Endocarditis: Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (33.33)24.3611
2020's4 (66.67)2.80

Authors

AuthorsStudies
Stahl, JP2
Varon, E2
Bru, JP2
Million, M1
Brouqui, P1
Raoult, D2
Sabourin, E1
Podglajen, I1
Fournier, PE1
Mainardi, JL1
Omarjee, L1
Jaquinandi, V1
Camarzana, A1
Rouleau, F1
Mezdad, TH1
Le Tourneau, T1
Mahe, G1
Belizna, C1
Angelakis, E1
Oddoze, C1

Other Studies

6 other studies available for hydroxychloroquine and Endocarditis

ArticleYear
Treatment of Coxiella burnetii endocarditis with hydroxychloroquine. Is it evidence-based?
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:5

    Topics: Coxiella burnetii; Endocarditis; Endocarditis, Bacterial; Humans; Hydroxychloroquine; Q Fever

2022
Re: Treatment of Coxiella burnetii endocarditis with hydroxychloroquine by Stahl et al.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:8

    Topics: Coxiella burnetii; Endocarditis; Endocarditis, Bacterial; Humans; Hydroxychloroquine; Q Fever

2022
'Treatment of Coxiella burnetii endocarditis with hydroxychloroquine' - Author's reply.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:8

    Topics: Coxiella burnetii; Endocarditis; Humans; Hydroxychloroquine; Q Fever

2022
Clinical and biological diagnosis and follow-up of patients treated for endovascular infections due to Coxiellaburnetii.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2023, Volume: 29, Issue:3

    Topics: Anti-Bacterial Agents; Doxycycline; Endocarditis; Endocarditis, Bacterial; Follow-Up Studies; Humans

2023
Improvement of Libman-Sacks Endocarditis With Combined Hydroxychloroquine-Vitamin K Antagonist Therapy in a Primary Antiphospholipid Syndrome Patient.
    Circulation journal : official journal of the Japanese Circulation Society, 2018, 08-24, Volume: 82, Issue:9

    Topics: Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Drug Therapy, Combination; Endocard

2018
Vitamin D and prolonged treatment with photosensitivity-associated antibiotics.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:12

    Topics: Adult; Aged; Anti-Bacterial Agents; Doxycycline; Endocarditis; Female; Humans; Hydroxychloroquine; M

2013